Download PDF
CC BY 4.0 · Glob Med Genet 2023; 10(04): 345-347
DOI: 10.1055/s-0043-1777275
Case Report

Early is Better: Report of a Cowden Syndrome

A. Di Nora
1   Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
,
G. Pellino
2   Department of Biomedical and Biotechnological Sciences, Medical Genetics, University of Catania, Catania, Italy
,
A. Di Mari
3   Department of Radiology, University of Catania, Catania, Italy
,
F. Scarlata
1   Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
,
F. Greco
1   Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
,
P. Pavone
1   Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

In the clinical practice, it is not common for pediatricians to visit children with overgrowth phenotype. When it happens, it is important to focus on the age of manifestations and research the pathogenic causes using appropriate genetic test. Cowden syndrome is one of these rare causes; it is an autosomal dominant genodermatosis characterized by multiple hamartomas of ectodermal, mesodermal, and endodermal origin. It is caused by loss of function mutations in the phosphatase and tensin homolog (PTEN) gene located on chromosome 10q23.1 Loss of function of the PTEN gene contributes to overgrowth and risk for a variety of cancers including breast, thyroid, endometrium, skin, kidneys, and colon. The early diagnosis of Cowden disease allows a careful monitoring of the patients who are facing the risk of cancer transformation, which is the principal complication of the condition.

Keywords

overgrowth syndrome - PTEN gene - neuroimaging

Ethical Approval

This study was conformed to the ethical guidelines of Declaration of Helsinki. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.


Authors' Contributions

Each author committed a substantial contribution to the conception or design of the work and to revise it critically for important intellectual content. In addition, each author approved the final version to be published. Conversely, each author agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.




Publication History

Article published online:
27 November 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Garofola C, Jamal Z, Gross GP. Cowden disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. . Accessed March 27, 2003 at: https://www.ncbi.nlm.nih.gov/books/NBK525984/
    Google Scholar
  • 2 Mahdi H, Mester JL, Nizialek EA, Ngeow J, Michener C, Eng C. Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study. Cancer 2015; 121 (05) 688-696
    CrossrefPubMedGoogle Scholar
  • 3 Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18 (02) 400-407
    CrossrefPubMedGoogle Scholar
  • 4 Cavaillé M, Ponelle-Chachuat F, Uhrhammer N. et al. Early onset multiple primary tumors in atypical presentation of Cowden syndrome identified by whole-exome-sequencing. Front Genet 2018; 9: 353
    CrossrefPubMedGoogle Scholar
  • 5 Rademacher S, Eickholt BJ. PTEN in autism and neurodevelopmental disorders. Cold Spring Harb Perspect Med 2019; 9 (11) a036780
    CrossrefPubMedGoogle Scholar
  • 6 Chen CY, Chen J, He L, Stiles BL. PTEN: tumor suppressor and metabolic regulator. Front Endocrinol (Lausanne) 2018; 9: 338
    CrossrefPubMedGoogle Scholar
  • 7 Ming M, He YY. PTEN in DNA damage repair. Cancer Lett 2012; 319 (02) 125-129
    CrossrefPubMedGoogle Scholar
  • 8 Liang H, He S, Yang J. et al. PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism. Cell Metab 2014; 19 (05) 836-848
    CrossrefPubMedGoogle Scholar
  • 9 Dhamija R, Weindling SM, Porter AB, Hu LS, Wood CP, Hoxworth JM. Neuroimaging abnormalities in patients with Cowden syndrome: retrospective single-center study. Neurol Clin Pract 2018; 8 (03) 207-213
    CrossrefPubMedGoogle Scholar
  • 10 Manor J, Lalani SR. Overgrowth syndromes-evaluation, diagnosis, and management. Front Pediatr 2020; 8: 574857 Erratum in: Front Pediatr. 2020;8:624141
    CrossrefPubMedGoogle Scholar
  • 11 Yachelevich N. Generalized overgrowth syndromes with prenatal onset. Curr Probl Pediatr Adolesc Health Care 2015; 45 (04) 97-111
    CrossrefPubMedGoogle Scholar
  • 12 Richmond EJ, Rogol AD. The child with tall stature and/or abnormally rapid growth 2018. Accessed April 2020 at: http://www.uptodate.com
    Google Scholar
  • 13 Dhamija R, Hoxworth JM. Imaging of PTEN-related abnormalities in the central nervous system. Clin Imaging 2020; 60 (02) 180-185
    CrossrefPubMedGoogle Scholar